273 related articles for article (PubMed ID: 17635633)
1. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope.
Medina MA; Muñoz-Chápuli R; Quesada AR
J Cell Mol Med; 2007; 11(3):374-82. PubMed ID: 17635633
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic strategies and agents in clinical trials.
Rosen L
Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Sessa C; Guibal A; Del Conte G; Rüegg C
Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of novel antiangiogenic therapies.
Scappaticci FA
Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy: Markers of response, "normalization" and resistance.
El Alaoui-Lasmaili K; Faivre B
Crit Rev Oncol Hematol; 2018 Aug; 128():118-129. PubMed ID: 29958627
[TBL] [Abstract][Full Text] [Related]
6. Do not say ever never more: the ins and outs of antiangiogenic therapies.
Quesada AR; Medina MÁ; Muñoz-Chápuli R; Ponce ÁL
Curr Pharm Des; 2010; 16(35):3932-57. PubMed ID: 21158731
[TBL] [Abstract][Full Text] [Related]
7. Targeting angiogenesis with integrative cancer therapies.
Yance DR; Sagar SM
Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
[TBL] [Abstract][Full Text] [Related]
8. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
9. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy.
Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E
Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163
[TBL] [Abstract][Full Text] [Related]
10. The combination of antiangiogenic therapy with other modalities.
O'Reilly MS
Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
[TBL] [Abstract][Full Text] [Related]
11. The interaction of radiation therapy and antiangiogenic therapy.
O'Reilly MS
Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
[TBL] [Abstract][Full Text] [Related]
12. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
Gagne P; Akalu A; Brooks PC
Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).
Maj E; Papiernik D; Wietrzyk J
Int J Oncol; 2016 Nov; 49(5):1773-1784. PubMed ID: 27826619
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and future directions for angiogenesis-based cancer therapies.
Scappaticci FA
J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
17. Angiogenic inhibitors: a new therapeutic strategy in oncology.
Gasparini G; Longo R; Toi M; Ferrara N
Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
[TBL] [Abstract][Full Text] [Related]
18. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
Gasparini G; Longo R; Fanelli M; Teicher BA
J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
[TBL] [Abstract][Full Text] [Related]
19. Current strategies and future directions of antiangiogenic tumor therapy.
Zhang ZL; Wang JH; Liu XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
[TBL] [Abstract][Full Text] [Related]
20. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
